Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 11 2024
0mins
Source: Newsfilter
Eliem Therapeutics Participation: Eliem Therapeutics, Inc. will participate in the Stifel 2024 Virtual Immunology and Inflammation Summit on September 17-18, 2024, with management team members engaging in 1x1 meetings.
Focus on Autoimmune Diseases: The company is dedicated to developing therapeutics for autoimmune-driven inflammatory diseases, notably advancing budoprutug, an anti-CD19 antibody targeting various conditions such as systemic lupus erythematosus and lupus nephritis.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
